98%
921
2 minutes
20
Infectious mononucleosis (IM) is a very common disease, and although in most instances, the patient develops an asymptomatic infection, other patients progress into an array of signs and symptoms that tend to be characteristic of the pathological process, guiding the clinician into choosing the right laboratory examinations under the suspicion of this illness. The most common symptoms are pharyngitis, lymphadenopathies and pyrexia, and the probabilities to develop this mononucleosis triad become greater with age. In other instances, IM can be a challenging disease to diagnose, mainly because the patient debuts with unusual symptoms such as nausea, skin eruptions, diarrhea and epigastric discomfort. The aim of the present article is to report the case of a 21-year-old female with a reactivation of IM, developing only multiple, asymptomatic lymph node enlargements in the head and neck region, showing no other sign or symptom.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069135 | PMC |
http://dx.doi.org/10.4103/jomfp.JOMFP_80_17 | DOI Listing |
Medicine (Baltimore)
August 2025
Department of Neurosurgery, Peking University People's Hospital, Xicheng District, Beijing, China.
Neurodegenerative diseases (NDs) are common chronic diseases with unknown etiology, and the association between virus and its pathogenesis is not clear. The aim of this study is to explore the role of virus in the pathogenesis of NDs by analyzing the causal effect between infectious mononucleosis (IM) mainly caused by Epstein-Barr virus and NDs. Based on the summary statistics of a large-scale genome-wide association study, we analyzed the causal effects of IM and NDs by Mendelian randomization (MR) using genetic variants as instrumental variables, including Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis.
View Article and Find Full Text PDFCureus
July 2025
Infectious Diseases, Globalmed University Clinic, Tbilisi, GEO.
Infectious mononucleosis (IM), caused by the Epstein-Barr virus (EBV), is primarily a self-limiting illness. However, it often mimics bacterial infections, such as bacterial tonsillitis, which can represent a diagnostic pitfall and, consequently, increase the risk of developing complications. The aim of this case report is to highlight the complications resulting from the incorrect differential diagnosis of EBV-induced IM and its clinical significance.
View Article and Find Full Text PDFViruses
August 2025
Department of Pathology, Microbiology and Immunology, New York Medical College, New York, NY 10595, USA.
Epstein-Barr Virus (EBV) is a causative agent of infectious mononucleosis and is strongly associated with Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma. EBV encodes a deubiquitinating enzyme, BPLF1, which is important for infectious virus production, B-cell immortalization, and tumorigenesis. To elucidate BPLF1's role, an affinity-based mass spectrometry screen was performed, which suggested that BPLF1 and mTOR interact.
View Article and Find Full Text PDFViruses
July 2025
China Center for Type Culture Collection, Wuhan University, Wuhan 430072, China.
The Epstein-Barr virus (EBV) is a prevalent virus linked to various diseases, including infectious mononucleosis (IM), nasopharyngeal carcinoma, and Hodgkin's lymphoma. Over the past few decades, EBV diagnostic strategies have evolved significantly-progressing from traditional serological assays and histopathology to more sensitive and specific molecular techniques such as nucleic acid amplification and high-throughput sequencing (HTS). While conventional methods remain valuable for their accessibility and established clinical use, they are often limited by sensitivity, speed, and multiplexing capability.
View Article and Find Full Text PDFBackground: The efficacy and safety of secukinumab up to week 52 in children and adolescents with moderate-to-severe chronic plaque psoriasis have been demonstrated previously (NCT03668613). Herein, we report the long-term efficacy, safety, and tolerability of secukinumab over a period of up to 208 weeks.
Methods: In this randomized open-label trial, patients (6 to < 18 years) were randomized 1:1 to receive low-dose (LD; N = 42) or high-dose (HD; N = 42) secukinumab stratified by weight (< 25 kg, 25 to < 50 kg, or ≥ 50 kg) and disease severity (moderate or severe).